Allecra Therapeutics

Executive Summary

Allecra Therapeutics is a private, clinical-stage biopharmaceutical company addressing antibiotic resistance with its lead candidate cefepime/enmetazobactam. In a pivotal Phase 3 trial, the combination demonstrated superiority over standard of care in patients with complicated urinary tract infections (cUTIs), a significant unmet need. The company is now preparing regulatory submissions in the U.S. and Europe. With positive efficacy and safety data, Allecra is well-positioned to bring a novel treatment option to market. The company's focus on overcoming emergent resistance mechanisms offers a differentiated approach in the growing antibiotic resistance space.

Upcoming Catalysts (preview)

• Q3 2026FDA NDA Submission for Cefepime/Enmetazobactam80% success
• Q4 2026European MAA Submission for Cefepime/Enmetazobactam80% success
• H2 2026Commercialization or Licensing Partnership Announcement70% success